EUVIMEDOpdag EUVIMED
Multizentrische StudieVergleichsstudie

Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?

Davide Fiore Bavaro, Giuseppe Accurso, Silvia Corcione, Antonio Vena, Michela Schenone, Lucia Diella, Teresa Fasciana, Maddalena Giannella, Daniele Roberto Giacobbe iD, Simone Mornese Pinna, Renato Pascale, Francesca Giovannenze and 6 more

Journal of Antimicrobial Chemotherapy · 2025

DOI: 10.1093/jac/dkaf080 ↗

At a glance

Multizentrische Studie in Journal of Antimicrobial Chemotherapy, 2025. Written by Davide Fiore Bavaro and 17 co-authors. Institution: Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy. Major MEDLINE topics: Pseudomonas Infections, Anti-Bacterial Agents, Bacteremia, Pseudomonas aeruginosa. Cited 6 times so far (Crossref); 43 references. Funded by: Pfizer, Shionogi, Tillotts Pharma.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Pseudomonas aeruginosa bloodstream infections (Pa-BSIs) are still a major cause of mortality in ICUs, posing many treatment uncertainties.

Methods

This multicentre, retrospective study analysed data from 14 Italian hospitals, including all consecutive adults developing Pa-BSI in ICU during 2021–22 and treated with antibiotics for at least 48 h. The primary aim was to identify predictors of 30 day mortality using Cox regression. Results were adjusted with inverse probability of treatment weighting (IPTW) and for immortal time bias.

Results

Overall, 170 patients were included. High-risk BSI (source: lung, intra-abdominal, CNS) occurred in 118 (69%) patients, and 54 (32%) had septic shock. In 37 (22%), 73 (43%), 12 (7%) and 48 (28%) the definitive backbone therapy was piperacillin/tazobactam, carbapenems, colistin or new antipseudomonal cephalosporins (ceftolozane/tazobactam, n = 20; ceftazidime/avibactam, n = 22; cefiderocol, n = 6), respectively. Moreover, 58 (34%) received a second drug as combination therapy. The incidence of 30 day all-cause mortality was 27.6% (47 patients). By Cox regression, Charlson comorbidity index, neutropenia, septic shock and high-risk BSI were independent predictors of 30 day mortality, while previous colonization by P. aeruginosa, use of antipseudomonal cephalosporins as definitive treatment, and combination therapy were shown to be protective. However, after IPTW adjustment, only the protective effect of antipseudomonal cephalosporins was confirmed (adjusted HR = 0.27, 95% CI = 0.10–0.69), but not for combination therapy. Hence, the treatment effect was calculated: antipseudomonal cephalosporins significantly reduced mortality risk [−17% (95% CI = −4% to −30%)], while combination therapy was beneficial only in the case of septic shock [−66% (95% CI = −44% to −88%].

Conclusions

In ICU, antipseudomonal cephalosporins may be the preferred target therapy for the treatment of Pa-BSI; in addition, initial combination therapy may be protective in the case of septic shock.

Subjects

MeSH terms (MEDLINE)

Pseudomonas InfectionsAnti-Bacterial AgentsBacteremiaPseudomonas aeruginosaPiperacillin, Tazobactam Drug CombinationCarbapenemsCephalosporinsHumansMaleFemaleRetrospective StudiesMiddle AgedAgedIntensive Care UnitsItalyAdultTreatment OutcomeAged, 80 and over

Substances

Anti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationCarbapenemsCephalosporins

Authors and institutions

  • Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, Pieve Emanuele, 20090 Milan, Italy.
  • Infectious Diseases Unit, IRCCS Humanitas Research Hospital, Via Manzoni 56, Rozzano, 20089 Milan, Italy.
  • Department of Anaesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, 90127 Palermo, Italy.
  • Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy.
  • Department of Infectious Diseases, Tufts University School of Medicine, Boston, MA 02111, USA.
  • Department of Health Sciences (DISSAL), University of Genoa, 16126 Genoa, Italy.

ORCID profiles: Daniele Roberto Giacobbe, Nicholas Geremia, Francesco Giuseppe De Rosa

Funding

  • Pfizer
  • Shionogi
  • Tillotts Pharma

Cite

APA

Bavaro, D. F., Accurso, G., Corcione, S., Vena, A., Schenone, M., Diella, L., Fasciana, T., Giannella, M., Giacobbe, D. R., Mornese Pinna, S., Pascale, R., Giovannenze, F., Geremia, N., Marino, A., Viale, P., De Rosa, F. G., Bassetti, M., & Bartoletti, M. (2025). Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkaf080

Vancouver

Bavaro DF, Accurso G, Corcione S, Vena A, Schenone M, Diella L, et al. Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?. Journal of Antimicrobial Chemotherapy. 2025. doi:10.1093/jac/dkaf080

BibTeX
@article{Bavaro2025,
  author = {Bavaro, Davide Fiore and Accurso, Giuseppe and Corcione, Silvia and Vena, Antonio and Schenone, Michela and Diella, Lucia and Fasciana, Teresa and Giannella, Maddalena and Giacobbe, Daniele Roberto and Mornese Pinna, Simone and Pascale, Renato and Giovannenze, Francesca and Geremia, Nicholas and Marino, Andrea and Viale, Pierluigi and De Rosa, Francesco Giuseppe and Bassetti, Matteo and Bartoletti, Michele},
  title = {Antipseudomonal cephalosporins versus piperacillin/tazobactam or carbapenems for the definitive antibiotic treatment of Pseudomonas aeruginosa bacteraemia: new kids on the ICU block?},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2025},
  doi = {10.1093/jac/dkaf080}
}
Start for free →